CoChat

Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1

Romano, Emanuela, Cotari, Jesse W., Barreira da Silva, Rosa, Betts, Brian C., Chung, David J., Avogadri, Francesca, Fink, Mitsu J., St Angelo, Erin T., Mehrara, Babak, Heller, Glenn, Münz, Christian, Altan-Bonnet, Gregoire, Young, James W. · 2012 · Blood
Cited by 50

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Human CD34+ progenitor-derived Langerhans-type dendritic cells (LCs) are more potent stimulators of T-cell immunity against tumor and viral antigens in vitro than are monocyte-derived DCs (moDCs). The exact mechanisms have remained elusive until now, however. LCs synthesize the highest amounts of IL-15R-α mRNA and protein, which binds IL-15 for presentation to responder lymphocytes, thereby signaling the phosphorylation of signal transducer and activator of transcription 5 (pSTAT5). LCs electroporated with Wilms tumor 1 (WT1) mRNA achieve sufficiently sustained presentation of antigenic peptides, which together with IL-15R-α/IL-15, break tolerance against WT1 by stimulating robust autologous, WT1-specific cytolytic T-lymphocytes (CTLs). These CTLs develop from healthy persons after only 7 days' stimulation without exogenous cytokines and lyse MHC-restricted tumor targets, which include primary WT1+ leukemic blasts. In contrast, moDCs require exogenous rhuIL-15 to phosphorylate STAT5 and attain stimulatory capacity comparable to LCs. LCs therefore provide a more potent costimulatory cytokine milieu for T-cell activation than do moDCs, thus accounting for their superior stimulation of MHC-restricted Ag-specific CTLs without need for exogenous cytokines. These data support the use of mRNA-electroporated LCs, or moDCs supplemented with exogenous rhuIL-15, as vaccines for cancer immunotherapy to break tolerance against self-differentiation antigens shared by tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-09-382200

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 36

  1. Palucka, 2010, Designing vaccines based on biology of human dendritic cell subsets., Immunity, 33, 464, 10.1016/j.immuni.2010.10.007 · DOI · Paper page
  2. Steinman, 2007, Lasker Basic Medical Research Award. Dendritic cells: versatile controllers of the immune system., Nat Med, 13, 1155, 10.1038/nm1643 · DOI · Paper page
  3. Rossi, 2005, Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity., J Immunol, 175, 1373, 10.4049/jimmunol.175.3.1373 · DOI · Paper page
  4. Szabolcs, 1996, Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate., Blood, 87, 4520, 10.1182/blood.V87.11.4520.bloodjournal87114520 · DOI · Paper page
  5. Caux, 1996, CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha., J Exp Med, 184, 695, 10.1084/jem.184.2.695 · DOI · Paper page
  6. Caux, 1997, CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis., Blood, 90, 1458, 10.1182/blood.V90.4.1458.1458_1458_1470 · doi:10.1182/blood.v90.4.1458.1458_1458_1470
  7. Ratzinger, 2004, Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells, J Immunol, 173, 2780, 10.4049/jimmunol.173.4.2780 · DOI · Paper page
  8. Bogunovic, 2006, Identification of a radio-resistant and cycling dermal dendritic cell population in mice and men., J Exp Med, 203, 2627, 10.1084/jem.20060667 · DOI · Paper page
  9. Klechevsky, 2008, Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells., Immunity, 29, 497, 10.1016/j.immuni.2008.07.013 · DOI · Paper page
  10. Haniffa, 2009, Differential rates of replacement of human dermal dendritic cells and macrophages during hematopoietic stem cell transplantation., J Exp Med, 206, 371, 10.1084/jem.20081633 · DOI · Paper page
  11. Banchereau, 2001, Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine., Cancer Res, 61, 6451
  12. Romano, 2011, Peptide-loaded Langerhans cells, despite increased IL-15 secretion and T-cell activation in vitro, elicit anti-tumor T-cell responses comparable to peptide-loaded monocyted-derived dendritic cells in vivo., Clin Cancer Res, 17, 1984, 10.1158/1078-0432.CCR-10-3421 · DOI · Paper page
  13. Munz, 2005, Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells., Blood, 105, 266, 10.1182/blood-2004-06-2492 · DOI
  14. Lodolce, 2001, T cell-independent interleukin 15R-alpha signals are required for bystander proliferation., J Exp Med, 194, 1187, 10.1084/jem.194.8.1187 · DOI · Paper page
  15. Waldmann, 2006, The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design., Nat Rev Immunol, 6, 595, 10.1038/nri1901 · DOI · Paper page
  16. Mortier, 2008, IL-15R-alpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation., J Exp Med, 205, 1213, 10.1084/jem.20071913 · DOI · Paper page
  17. Mohamadzadeh, 2001, Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells., J Exp Med, 194, 1013, 10.1084/jem.194.7.1013 · DOI
  18. Dubsky, 2007, IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL., Eur J Immunol, 37, 1678, 10.1002/eji.200636329 · DOI
  19. Witmer-Pack, 1987, Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells., J Exp Med, 166, 1484, 10.1084/jem.166.5.1484 · DOI · Paper page
  20. Ratzinger, 2005, Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells [erratum]., J Immunol, 174, 3818, 10.4049/jimmunol.174.6.3818 · doi:10.4049/jimmunol.174.6.3818
  21. Eisenwort, 2011, Identification of TROP2 (TACSTD2), an EpCAM-like molecule, as a specific marker for TGF-[beta]1-dependent human epidermal Langerhans cells., J Invest Dermatol, 131, 2049, 10.1038/jid.2011.164 · DOI
  22. van der Aar, 2007, Cutting edge: loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition., J Immunol, 178, 1986, 10.4049/jimmunol.178.4.1986 · DOI · Paper page
  23. de Saint-Vis, 1998, The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation., J Immunol, 160, 1666, 10.4049/jimmunol.160.4.1666 · DOI · Paper page
  24. Maecker, 2005, Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT., BMC Immunol, 6, 17, 10.1186/1471-2172-6-17 · DOI
  25. Pinilla-Ibarz, 2006, Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein., Leukemia, 20, 2025, 10.1038/sj.leu.2404380 · DOI
  26. Brilot, 2007, NK cell survival mediated through the regulatory synapse with human DCs requires IL-15R-alpha., J Clin Invest, 117, 3316, 10.1172/JCI31751 · DOI
  27. Jonuleit, 1997, Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions., Eur J Immunol, 27, 3135, 10.1002/eji.1830271209 · DOI · Paper page
  28. Boublikova, 2006, Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring., Leukemia, 20, 254, 10.1038/sj.leu.2404047 · doi:10.1038/sj.leu.2404047
  29. Ferlazzo, 2004, Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs., Proc Natl Acad Sci U S A, 101, 16606, 10.1073/pnas.0407522101 · DOI · Paper page
  30. Su, 2003, Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells., Cancer Res, 63, 2127
  31. Oh, 2004, IL-15/IL-15R-alpha-mediated avidity maturation of memory CD8+ T cells., Proc Natl Acad Sci U S A, 101, 15154, 10.1073/pnas.0406649101 · DOI
  32. Oh, 2008, IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis., Proc Natl Acad Sci U S A, 105, 5201, 10.1073/pnas.0801003105 · DOI
  33. Vera, 2009, Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7., Mol Ther, 17, 880, 10.1038/mt.2009.34 · DOI
  34. Park, 2004, Suppression of IL-7Ralpha transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival., Immunity, 21, 289, 10.1016/j.immuni.2004.07.016 · DOI · Paper page
  35. Miller, 2005, Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer., Blood, 105, 3051, 10.1182/blood-2004-07-2974 · DOI · Paper page
  36. Hsu, 2005, Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes., Blood, 105, 4878, 10.1182/blood-2004-12-4825 · DOI · Paper page

Cited by

See all 50

Metadata

Authors
Romano, E., Cotari, J. W., Barreira da Silva, R., Betts, B. C., Chung, D. J., Avogadri, F., Fink, M. J., St Angelo, E. T., Mehrara, B., Heller, G., Münz, C., Altan-Bonnet, G., & Young, J. W.
Venue
Blood
Published
2012-05-31
Volume
119
Issue
22
Pages
5182-5190
ISSN
  • 0006-4971
  • 1528-0020
Cited by
50
References
7
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1. https://app.cochat.ai/papers/10.1182/blood-2011-09-382200
The paper
Romano, E., Cotari, J. W., Barreira da Silva, R., Betts, B. C., Chung, D. J., Avogadri, F., Fink, M. J., St Angelo, E. T., Mehrara, B., Heller, G., Münz, C., Altan-Bonnet, G., & Young, J. W. (2012). Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1. Blood. https://doi.org/10.1182/blood-2011-09-382200

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.